Todd E. Golde, MD, PhD, Emory University, Atlanta, GA, comments on the future of preclinical evaluation of immune modulatory therapies in Alzheimer’s disease. While several long-term studies have recruited patients at an early stage in the AD continuum, these have tested agents since shown the have limited clinical efficacy, such as solanezumab (NCT02008357). Prevention studies with newer antibodies that have produced positive Phase III data are now underway, but it will take numerous years to gauge their value in a preclinical setting. Prof. Golde notes several concerns regarding the practicability of prevention studies with anti-amyloid antibodies. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
